Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss.

Few dermatologic conditions carry as much anxiety and emotional distress as hair loss resulting from a disease condition such as alopecia areata or as a result of cytotoxic drug treatment, e.g., after chemotherapy. Bimatoprost 0.03% solution is a Food and Drug Administration-approved prescription product indicated for the treatment of eyelash hypotrichosis. The product was investigated in a double-masked, randomized, and placebo-controlled study in patients who had significant eyelash loss or hypotrichosis as a result of chemotherapy. Once-daily treatment with bimatoprost ophthalmic solution 0.03% to the upper eyelid margin restored eyelash growth and prominence more quickly than the slower, natural course of recovery observed in the vehicle control subjects. The eyelash prominence measured using a validated Global Eyelash Assessment (GEA) scale demonstrated a statistically significant increase over placebo following 6 months of treatment. Efficacy was also demonstrated using a validated objective digital image analysis methodology to show significant increase in eyelash length, thickness/fullness, and darkness in these patients. Bimatoprost was found to be well tolerated over the 1-year treatment period.
AuthorsGurpreet S Ahluwalia
JournalThe journal of investigative dermatology. Symposium proceedings / the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research (J Investig Dermatol Symp Proc) Vol. 16 Issue 1 Pg. S73-6 (Dec 2013) ISSN: 1529-1774 [Electronic] United States
PMID24326568 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Amides
  • Antineoplastic Agents
  • Dermatologic Agents
  • Cloprostenol
  • Bimatoprost
  • Amides (adverse effects, therapeutic use)
  • Antineoplastic Agents (adverse effects)
  • Bimatoprost
  • Cloprostenol (adverse effects, analogs & derivatives, therapeutic use)
  • Dermatologic Agents (adverse effects, therapeutic use)
  • Double-Blind Method
  • Eyelashes
  • Humans
  • Hypotrichosis (chemically induced, drug therapy)
  • Patient Satisfaction
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: